X0306 4 2015-04-06 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532219 Quinn Anthony 33 HAYDEN AVE LEXINGTON MA 02421 false true false false EVP, CMO & Head of R&D Common Stock 2015-04-06 4 A false 42 76.88 A 25637 D Common Stock 2015-04-06 4 M false 10000 0.95 A 35637 D Common Stock 2015-04-06 4 M false 9503 23 A 45140 D Common Stock 2015-04-06 4 S false 29503 93.76 D 15637 D Stock Option (Right to Buy) 0.95 2015-04-06 4 M false 10000 0 D 2019-10-07 Common Stock 10000 8964 D Stock Option (Right to Buy) 23 2015-04-06 4 M false 9503 0 D 2021-12-20 Common Stock 9503 20497 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c). The reporting person is voluntarily reporting this transaction as of 04/06/2015, but the actual transaction took place on 12/31/2014, the last trading day of the option period under the ESPP. In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period. The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 6, 2015. The Stock Option granted the reporting person an option to purchase 101,080 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 08/31/2010, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. /s/ Chris Heberlig, Attorney-in-Fact 2015-04-08